Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Down 70.6% in June

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) was the target of a large decrease in short interest in June. As of June 30th, there was short interest totaling 65,392 shares, a decrease of 70.6% from the June 15th total of 222,527 shares. Currently, 7.1% of the shares of the stock are short sold. Based on an average trading volume of 5,387,370 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Cuprina Holdings (Cayman) Trading Down 6.0%

Cuprina Holdings (Cayman) stock traded down $0.32 during mid-day trading on Friday, hitting $4.97. The company had a trading volume of 31,012 shares, compared to its average volume of 5,210,070. The firm’s fifty day moving average is $3.57. Cuprina Holdings has a 12-month low of $1.76 and a 12-month high of $76.00. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.07.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) last issued its quarterly earnings data on Monday, April 27th. The company reported ($0.40) EPS for the quarter. The business had revenue of $0.01 million during the quarter.

Cuprina Holdings (Cayman) Company Profile

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.